Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 15/20 | 0.44 |
| ▸ | HTR2A | P28223 | 3/20 | 0.41 |
| ▸ | HTR2C | P28335 | 3/20 | 0.41 |
| ▸ | HTR7 | P34969 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4267456 | 0.88 | HTR6 (0.54) | HTR6HTR2AHTR2CHTR7KDM4E | |
| SCHEMBL4276532 | 0.86 | HTR6 (0.40) | HTR6HTR2AHTR2CHTR7SMN1; SMN2 | |
| SCHEMBL4278723 | 0.78 | HTR6 (0.54) | HTR6HTR2AHTR2CHTR7KDM4E | |
| SCHEMBL4274948 | 0.77 | HTR6 (0.53) | HTR6HTR2AHTR2CHTR7KDM4E | |
| SCHEMBL4267488 | 0.74 | HTR6 (0.52) | HTR6HTR2AHTR2CHTR7 | |
| SCHEMBL4268401 | 0.74 | HTR6 (0.52) | HTR6HTR2AHTR2CHTR7 | |
| SCHEMBL13657144 | 0.73 | KDM4E (0.49) | HTR6KDM4ESMN1; SMN2 | |
| SCHEMBL4275875 | 0.73 | MET (0.51) | HTR6 | |
| SCHEMBL4271798 | 0.72 | HTR6 (0.50) | HTR6HTR2AHTR2CHTR7SMN1; SMN2 | |
| SCHEMBL4270145 | 0.72 | HTR6 (0.43) | HTR6HTR2AHTR2CHTR7KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7608717-B2 | Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-10-27 | — | — | US | claimed |
| US-20080070943-A1 | Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2008-03-20 | — | — | US | claimed |
| US-7291736-B2 | Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-11-06 | — | — | US | claimed |
| EP-1648891-A1 | SULFONYLDIHYDROIMID- AZOPYRIDINONE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2006-04-26 | — | — | EP | claimed |
| WO-2005010003-A1 | SULFONYLDIHYDROIMID- AZOPYRIDINONE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2005-02-03 | — | — | WO | claimed |
| US-20050020596-A1 | Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-01-27 | — | — | US | claimed |
| US-7608717-B2 | Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-10-27 | — | — | US | disclosed |
| US-20080070943-A1 | Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2008-03-20 | — | — | US | disclosed |
| US-7291736-B2 | Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-11-06 | — | — | US | disclosed |
| EP-1648891-A1 | SULFONYLDIHYDROIMID- AZOPYRIDINONE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005010003-A1 | SULFONYLDIHYDROIMID- AZOPYRIDINONE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20050020596-A1 | Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070943-A1 | Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR2C | HTR6 1/4885HTR2A 6/4885HTR2C 3/4885 |
| US-20050020596-A1 | Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR2C | HTR6 1/4885HTR2A 6/4885HTR2C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.